Overview
PTC Therapeutics Q3 revenue rises to $211 mln, helped by Sephience launch
PTC reports Q3 net income of $15.9 mln, reversing previous year's loss of $106.7 mln
Outlook
PTC expects full-year 2025 revenue of $750 mln to $800 mln
Company projects 2025 GAAP R&D and SG&A expenses of $805 mln to $835 mln
PTC anticipates 2025 non-GAAP R&D and SG&A expenses of $730 mln to $760 mln
Result Drivers
SEPHIENCE LAUNCH - Strong initial uptake of Sephience with $19.6 mln in Q3 revenue and 521 start forms in the US
ROYALTY REVENUE - Increase in royalty revenue to $70.8 mln, driven by Evrysdi sales
DMD FRANCHISE DECLINE - Revenue from DMD franchise decreased, with Translarna and Emflaza revenues lower than previous year
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $130.96 mln | ||
Q3 Net Income | $15.89 mln | ||
Q3 Basic EPS | $0.20 | ||
Q3 Operating Expenses | $207.99 mln | ||
Q3 Operating Income | $3.01 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PTC Therapeutics Inc is $70.00, about 3% above its November 3 closing price of $67.93
Press Release: ID:nPn117zpva
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)